This review discusses evidence in support of the use of fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg administered via a single inhaler (Trelegy Ellipta 100) for the treatment of chronic obstructive pulmonary disease (COPD). Trelegy Ellipta 100 is licensed in New Zealand for the maintenance treatment of adults with moderate-to-severe COPD who require treatment with a long acting muscarinic antagonist, long-acting beta2 agonist and an inhaled corticosteroid,1 and is now fully subsidised for this use (with Special Authority criteria).
This publication has been commissioned and funded by GSK. The content is based on published studies and the author’s opinions and may not reflect the views of GSK. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. All trademarks mentioned in this review are the property of their respective owners.
Please login below to download this issue (PDF)